• Adjusted gross profit up 30% (+1% on an organic basis) to £182.3m (2018: £140.1m); with adjusted gross profit on an organic basis excl. Foscavir and UK Specials business +7%
  • Adjusted EBITDA up 33% (+4% on an organic basis) to £100.8m (2018: £76.0m); with adjusted EBITDA growth on an organic basis excl. Foscavir and UK Specials business +23%
  • Adjusted EPS up 20% to 54.4p (2018: 45.4p), continuing double digit EPS growth each year since IPO
  • Reported EPS of 4.0p (2018: 22.9p)
  • Profit before income tax of £12.3m (2018: £35.9m)
  • Net debt as at 30 June 2019 of £252.4m, representing a strong cash flow performance and pro forma leverage of 1.99x
  • Full year dividend increased 20% to 6.7p (2018: 5.6p)